Audit: QRS - Omega-3 for Health & Longevity

Audit conducted on 23/08/2026 04:28 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol regimens (ER 379–383), time-to-effect values (ER 436), benefit/risk tier headings (ER 155–235, 259–309), contraindications (ER 353–357), interactions (ER 331–349), biomarker table (ER 470–480), qualitative markers (ER 484–489).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s hedges are carried through: “stays unsettled” (ER “remains unsettled”), “carries the atrial fibrillation and bleeding signals”, “risk signal” for prostate cancer.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds (“above 3 g/day”, “above 1 g/day”, “within 7 days”) and severity words are preserved unchanged from ER 353–357.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid Omega-3” list; Key Interactions only from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no trial names, no NCT identifiers, no expert names and no brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Protocol panel and Monitoring table give actionable targets; Benefits/Risks tiers are stated objectively without alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Marine or algal … with food, indefinitely”), never as an instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions in the QRS’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or “must” anywhere in the document body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are expanded as in the ER (“eicosapentaenoic plus docosahexaenoic acid”, “alanine aminotransferase”, “High-sensitivity C-reactive protein”); remaining technical labels are ER-verbatim gate labels required by 4.2.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items reduced to label plus severity word; benefit/risk items reduced to bare headings; monitoring rows are phrase-length.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Omega-3 Index targeting, apolipoprotein B, and rhythm screening are pitched at a proactive, self-testing audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Food-first alternative, index-guided titration and a nine-marker monitoring panel all assume effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (triglycerides below 80 mg/dL, HbA1c below 5.4%) are tighter than population cut-offs.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance foregrounds the dose-dependent atrial fibrillation excess, the risk most relevant to long-term high-dose users.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Slower biological aging on methylation clocks”; the string “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout; the plain-language wording in the at-a-glance is mandated by item 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified against the template: lines 440, 477, 519, 573, 592, 711, 539, 551, tier labels at 522/525/528/531 and 576/579/582/585, table headers at 596–598.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Machine-diffed against the template span list: all 38 template variables present, with marker_#_* expanded to 1–9 and qualitative_item_# expanded to 1–6 as intended.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Full structural diff against the template shows changes confined to the metadata block, the title, and the checklist-addressed spans; all CSS, comments and markup are byte-identical.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section drawn on by the QRS is empty; every benefit tier, risk tier, gate list and monitoring row has source content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels are ER-verbatim (“Standard maintenance protocol”, “Food-first alternative”, “High-dose pharmaceutical approach”, ER 379/381/383); interaction labels are ER-verbatim apart from the example-drug trimming expressly permitted by 9.5.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table column 1 exactly (ER 472–480); benefit and risk items match the ER’s #### headings.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points in the file; the ER’s “⚠️ Conflicted” markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against its ER source — mechanistic rationale, magnitudes and citations stripped from Benefits/Risks, trailing clauses stripped from both gates, example-drug lists trimmed, monitoring “Why” cells reduced to a single clause. No second-page content exists.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in the rendered body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: omega_3_2026-0823-0001_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0823-0406.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: omega_3_2026-0823-0001_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: all nine keys are trimmed and unquoted except the colon-bearing duration.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Omega-3 for Health & Longevity - Quick Reference Sheet, matching ER frontmatter canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Omega-3 for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/23/2026, correctly derived from 2026-0823-0406.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template’s standard subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 tracks the Conclusion (ER 509–511) in order: dietary fat not a drug, the two established effects, the formulation-specific mood effect, the unsettled cardiovascular question, the atrial fibrillation and tolerability signals.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence in ER 509–511.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “blood fats”, “irregular heart rhythm”, “the two marine forms”, “digestive complaints”; no acronyms and no clinical-register vocabulary.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial is named; REDUCE-IT and STRENGTH are referred to only obliquely via “stays unsettled”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears; “above about a gram daily” is a dose threshold, not an effect size.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from “Populations who should avoid Omega-3” (ER 353–357).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER entries are present, none added: allergy, active bleeding/surgery window, atrial fibrillation, severe hepatic impairment, third-trimester pregnancy.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–546: five <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale clauses (“where lipid handling is unpredictable”, “where observational data suggest a postpartum bleeding signal”) are stripped; no dash-led clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 7 days”, “above 3 g/day”, “above 1 g/day”, “(Child-Pugh Class C)”, “at prescription doses”, “third trimester” all retained; only the explanatory gloss inside the Child-Pugh parenthesis is trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies five such populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items come from the ER’s interaction bullets (ER 331–349).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are present and none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 554–563: ten <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to the ER’s bold label plus its severity word (“Caution”/”Monitor”); all mechanistic sentences are stripped and no dash-led clauses remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER parenthesis survives in trimmed form — e.g. “(apixaban, rivaroxaban)”, “(aspirin, clopidogrel)”, “(vitamin E, garlic, ginkgo)”, “(tacrolimus, ciclosporin)”; none is dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten interactions and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER “Therapeutic Protocol” bullets 1–3 (ER 379–383).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three dosing routes — maintenance supplementation, food-first, and high-dose pharmaceutical — are the ER’s own leading three bullets and the only actionable regimens it defines.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Lines 444–473: all nine spans carry ER-derived content, with the doses “1–2 g/day”, “2–3 servings weekly” and “4 g/day” matching ER 379/381/383.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Triglycerides, blood pressure, and joint pain/mood are exactly the three effects the ER’s “Time to effect” bullet timestamps (ER 436).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER’s High-tier ordering: triglyceride reduction, blood pressure reduction, then depressive symptoms (paired with the Medium-tier joint pain finding).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Lines 483–511: “4–8 weeks”, “8–12 weeks”, “8–12 weeks” match ER 436; the sub-lines draw on ER 159, 165 and 171 plus the 3–4 month index steady state (ER 137/436).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (ER 436), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen items map one-to-one onto the ER’s #### benefit headings (ER 157–235).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; all Magnitude figures, mechanism sentences and “Net reading” commentary are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit item; the ER’s “⚠️ Conflicted” markers are also dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items map one-to-one onto the ER’s #### risk headings (ER 261–309).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 575–586.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; hazard ratios, event percentages and regulatory commentary are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk item; the ER’s “⚠️ Conflicted” markers are also dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER’s “Monitoring Protocol & Defining Success” biomarker table (ER 470–480).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are present with ER-verbatim targets: Omega-3 Index, triglycerides, LDL cholesterol, apolipoprotein B, hs-CRP, blood pressure, resting heart rhythm, glycated haemoglobin, alanine aminotransferase.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 705 condenses ER 468: index at 4 months, lipids and apolipoprotein B at 8–12 weeks, then every 6–12 months, blood pressure quarterly, rhythm annually over 60.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s “Qualitative markers worth tracking” list (ER 484–489).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present: aftertaste/eructation, joint stiffness, mood, palpitations, skin and eye dryness, training recovery.

Issues 23/08/2026 04:28

Pass rate 100.00%. No issues found.

Issues 23/08/2026 04:20

1. 1.3 — Atrial fibrillation risk narrowed: [at_a_glance] (line 433) states “Regular use above about a gram daily raises the rate of an irregular heart rhythm”, dropping the ER Conclusion’s qualifier “particularly” (ER line 511) and thereby implying no risk at or below 1 g/day, which the ER contradicts at line 265.

Fixes 23/08/2026 04:20

1. 1.3 — Atrial fibrillation risk qualifier restored: In [at_a_glance] changed “Regular use above about a gram daily raises the rate of an irregular heart rhythm” to “Regular use, particularly above about a gram daily, raises the rate of an irregular heart rhythm”, matching the ER Conclusion’s hedge and no longer implying zero risk at or below 1 g/day.

Issues 23/08/2026 04:12

1. 4.5 — Sheet overflows one A4 page: The action_#_sub cells (lines 450, 461, 472), the time_#_sub cells (lines 489, 500, 511), marker_4_why (line 643), monitoring_cadence (line 705) and the long parenthetical drug lists in caution_items (lines 557, 560) carry full explanatory sentences and six-item example lists that wrap to four and five lines in their ~218 px and ~348 px columns, pushing the sheet well past a single A4 page.

Fixes 23/08/2026 04:12

1. 4.5 — Protocol sub-cells condensed: Rewrote all three action_#_sub cells as compact fragments, e.g. action_1_sub from “Combined eicosapentaenoic and docosahexaenoic acid from a marine or algal source, taken with food, continued indefinitely; the Omega-3 Index confirms the dose is sufficient.” to “Marine or algal eicosapentaenoic plus docosahexaenoic acid, with food, indefinitely; Omega-3 Index confirms sufficiency.”
2. 4.5 — Time-to-effect sub-cells shortened: Trimmed all three time_#_sub cells, including time_3_sub from 165 to 117 characters by dropping the redundant “joint pain in rheumatoid arthritis” already carried by the cell label.
3. 4.5 — Interaction example lists trimmed: Shortened the parenthetical drug lists in caution_items to two or three representative examples each (e.g. “vitamin E, garlic, ginkgo, nattokinase, high-dose curcumin, ginger” to “vitamin E, garlic, ginkgo”), removing four wrapped lines from the gate column without dropping any list.
4. 4.5 — Monitoring “Why” cells and cadence condensed: Cut marker_4_why from 113 to 76 characters, tightened marker_8_why, and reduced monitoring_cadence from 199 to 155 characters while keeping every retest interval.
5. 4.5 — Qualitative items tightened: Removed trailing clauses from qualitative items 3, 4 and 6 (e.g. “which warrant a rhythm check rather than watchful waiting” to “which warrant a rhythm check”).